10-Q: Quarterly report
Express News | News On Avista Public Acquisition Corp. II (AHPA,OABIV) Now Under OABI
OmniAb Announces Completion of Spin-Off and Business Combination
Ligand Announces That Janssen Has Received Approval From U.S FDA For Tecvayli For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma; Under The Terms OmniAb Is Eligible To Receive A $25M Milestone Payment Upon The First Commercial Sale
First FDA approval of a bispecific antibody discovered using OmniAb technologyOmniAb, Inc. is eligible to receive a $25 million milestone upon first commercial sale in the United StatesLigand Pharmace
SPAC APAC Shareholders Approve Merger With Ligand Spinoff OmniAb
Avista Public Acquisition Corp. II And OmniAb Business Combination Approved By APAC Shareholders Closing Scheduled for November 1;
APAC Shareholder Approval Obtained, Closing Scheduled for November 1, 2022Ligand "Regular Way" and "Ex-Distribution" and OmniAb "When-Issued" Set to Begin Trading on October 25, 2022Ligand Pharmaceuti
Express News | OmniAb Business Combination Approved by APAC Hldrs
Catalyst Watch: Tech Heavyweights Report, Mobileye IPO and Twitter-Tesla-Musk Drama Redux
Ligand Announces Record Date And Details For Distribution For OmniAb Spin-Off
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of shares of common stock of Om
Express News | Avista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinary General Meeting to Vote on Proposed Business Combination
Press Release: Avista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinary General Meeting to Vote on Proposed Business Combination
Avista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinary General Meeting to Vote on Proposed Business Combination PR Newswire NEW YORK, Oc
Press Release: Avista Public Acquisition Corp. II -2-
This news release contains forward-looking statements by APAC that involve risks and uncertainties and reflect APAC's judgment as of the date of this release. Words such as "plans," "believes," "expec
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
Janssen Biotech Inc, a Johnson & Johnson (NYSE:JNJ) unit, received European conditional approval for Tecvayli (teclistamab) as monotherapy for relapsed or refractory multiple myeloma. Teclistamab
Press Release: Ligand Announces That Janssen Has Received Approval From European Commission for TECVAYLI(R) (Teclistamab) for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI(R) (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma First European Co
Press Release: Ligand Announces That Janssen Has -2-
This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Words such as "plans," "believes," "e
Press Release: Ligand Reports Second Quarter 2022 Financial Results
Ligand Reports Second Quarter 2022 Financial Results Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif.--(BUSINESS WIRE)--August 08, 2022-- Li
Express News | Ligand Pharmaceuticals Sees FY22 Rev $169M-$188M >LGND
Express News | Ligand Pharmaceuticals Expects 2022 Captisol Sales of $55 M to $60 M and Contract Rev of $52 M to $6
Express News | Ligand Pharmaceuticals Expects 2022 Royalties of $62 M to $66 M >LGND
Express News | Ligand Pharmaceuticals 2Q Adj EPS Ex-Impact of Gross Profit, Net of Tax, for Captisol Sales Related
No Data